Hemab Therapeutics Holdings, Inc.
COAG
$54.94
$0.991.84%
NASDAQ
| 06/30/2026 | |||||
|---|---|---|---|---|---|
| Revenue | -- | ||||
| Total Other Revenue | -- | ||||
| Total Revenue | -- | ||||
| Cost of Revenue | -- | ||||
| Gross Profit | -- | ||||
| SG&A Expenses | 38.35% | ||||
| Depreciation & Amortization | -- | ||||
| Other Operating Expenses | -- | ||||
| Total Operating Expenses | 10.45% | ||||
| Operating Income | -10.45% | ||||
| Income Before Tax | -6.08% | ||||
| Income Tax Expenses | 708.33% | ||||
| Earnings from Continuing Operations | -6.45% | ||||
| Earnings from Discontinued Operations | -- | ||||
| Extraordinary Item & Accounting Change | -- | ||||
| Minority Interest in Earnings | -- | ||||
| Net Income | -6.45% | ||||
| EBIT | -10.45% | ||||
| EBITDA | -10.47% | ||||
| EPS Basic | 96.66% | ||||
| Normalized Basic EPS | 96.67% | ||||
| EPS Diluted | 96.66% | ||||
| Normalized Diluted EPS | 96.67% | ||||
| Average Basic Shares Outstanding | 3,083.01% | ||||
| Average Diluted Shares Outstanding | 3,083.01% | ||||
| Dividend Per Share | -- | ||||
| Payout Ratio | -- | ||||